ID   CUTO-8
AC   CVCL_C8T9
SY   CUTO8; Colorado University Thoracic Oncology 8
DR   ArrayExpress; E-MTAB-11342
DR   Wikidata; Q123031002
RX   DOI=10.1101/2022.06.08.495301;
RX   PubMed=35933914;
CC   Doubling time: 28 +- 3.1 hours (PubMed=35933914).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=35933914).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=35933914).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (DOI=10.1101/2022.06.08.495301; PubMed=35933914).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly293fs*13 (c.876dupA); Zygosity=Homozygous (PubMed=35933914).
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-04-25; Version: 4
//
RX   DOI=10.1101/2022.06.08.495301;
RA   Licciardello M.P., Zhang C., Le A.T., Doebele R.C., Clarke P.A.,
RA   Workman P.;
RT   "Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90
RT   inhibitors.";
RL   bioRxiv 2022:06.08.495301-06.08.495301(2022).
//
RX   PubMed=35933914; DOI=10.1016/j.lungcan.2022.07.010;
RA   Bokhari A.A.A., Lai W.-Y., Le A.T., Gabre J.L., Chuang T.-P.,
RA   Fransson S., Bergman B., Djos A., Chen N., Martinsson T.,
RA   Van den Eynden J., Doebele R.C., Palmer R.H., Hallberg B., Umapathy G.;
RT   "Novel human-derived EML4-ALK fusion cell lines identify
RT   ribonucleotide reductase RRM2 as a target of activated ALK in
RT   NSCLC.";
RL   Lung Cancer 171:103-114(2022).
//